{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:05:08Z","timestamp":1761807908207,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.maturitas.2014.11.017","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T22:37:27Z","timestamp":1417473447000},"page":"148-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Managing multiple myeloma in the over 70s: A review"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1397-654X","authenticated-orcid":false,"given":"Andrew J","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","key":"10.1016\/j.maturitas.2014.11.017_bib0005"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0245","unstructured":"Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (eds). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http:\/\/seer.cancer.gov\/csr\/1975_2007\/, based on November 2009 SEER data submission, posted to the SEER Web site 2010."},{"key":"10.1016\/j.maturitas.2014.11.017_bib0015","article-title":"Guidelines for the diagnosis and management of multiple myeloma","author":"Bird","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0020","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0025","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0030","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)","volume":"147","author":"Bird","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0045","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvements in long-term survival of younger patients with multiple myeloma and the impact of novel therapies","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0050","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than 50 years presents with more favourable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0055","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>3.0.CO;2-B","article-title":"Aging and pharmacology","volume":"80","author":"Vestal","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0749-0690(18)30188-5","article-title":"Pharmacology of cancer chemotherapy in the older person","volume":"13","author":"Baker","year":"1997","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"10.1016\/j.maturitas.2014.11.017_bib0065","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0749-0690(18)30615-3","article-title":"Altered pharmacokinetics in the elderly","volume":"6","author":"Yuen","year":"1990","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0009-9236(97)90166-1","article-title":"Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions","volume":"61","author":"Sotaniemi","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.maturitas.2014.11.017_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2052-1839-13-9","article-title":"Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network","volume":"13","author":"Howell","year":"2013","journal-title":"BMC Hematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0080","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0085","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0090","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study","volume":"82","author":"Riccardi","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0095","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"2 (Dec 19)","key":"10.1016\/j.maturitas.2014.11.017_bib0100","doi-asserted-by":"crossref","first-page":"e000308","DOI":"10.1136\/bmjopen-2011-000308","article-title":"Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting","volume":"1","author":"O\u2019Callaghan","year":"2011","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"10.1016\/j.maturitas.2014.11.017_bib0105","first-page":"SN18","article-title":"Epidemiology of primary hyperparathyroidism in Europe","volume":"17","author":"Adami","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0115","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.critrevonc.2009.08.002","article-title":"Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience","volume":"73","author":"Giron\u00e9s","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0125","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"Oct 7","key":"10.1016\/j.maturitas.2014.11.017_bib0130","article-title":"Curing myeloma at last: defining criteria and providing the evidence","author":"Barlogie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0140","unstructured":"NICE Technology Appraisal TA311. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation. [published April 2014]."},{"key":"10.1016\/j.maturitas.2014.11.017_bib0145","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0150","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0155","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995\u20132005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age","volume":"19","author":"McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23561","article-title":"Safety and efficacy of upfront plerixafor +G-CSF versus placebo+G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients >60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma","volume":"88","author":"Micallef","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2169\/internalmedicine.52.8390","article-title":"Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"52","author":"Muta","year":"2013","journal-title":"Intern Med"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/10428194.2011.606942","article-title":"Feasibility of autologous hematopoietic stem cell transplant in patients aged \u226570 years with multiple myeloma","volume":"53","author":"Bashir","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0175","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a metaanalysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0250","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0185","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0190","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0195","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0200","article-title":"Novel approaches to treatment of double refractory multiple myeloma","author":"Lee","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0205","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.12129","article-title":"Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"160","author":"Berenson","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0215","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0220","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients. The Nordic Myeloma Study Group","volume":"53","author":"Knudsen","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0268-960X(99)90014-0","article-title":"Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma","volume":"13","author":"Clark","year":"1999","journal-title":"Blood Rev"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0235","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.11.017_bib0240","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214003831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214003831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:00:22Z","timestamp":1759914022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214003831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0378512214003831"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.11.017","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing multiple myeloma in the over 70s: A review","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}